"I think that it is correct to say that New Chapter and I found each other. I was looking for a way to extract a potential plant based anticancer product and the company was interested in exploring novel ways of treating inflammation. I have always sought new therapeutic solutions to complex research problems that apply to prevention and control of disease; this goal fits well with the mission, vision and philosophy of New Chapter which is a company aimed at bringing novel and exciting healthcare products to the marketplace. Their genuine desire to explore and understand the science behind their products and its importance with respect to optimally developing products of value for mankind is both admirable and highly unusual in the greater nutraceutical world. I am extremely proud of my collaborative association with this fine company."

Dr. Newman received his undergraduate training at the University of Rhode Island and graduate training at the University of Connecticut where he obtained MS and Ph.D. degrees in pharmacology and toxicology. Postgraduate work was done at the Medical School of Georgia and at the University of Vermont Medical School. After a sabbatical at Stanford University in 1983, Dr. Newman joined the faculty of the University of Texas M. D. Anderson Cancer Center.

He is a Professor of Experimental Therapeutics and holds the D.B. Land Professorship. Dr. Newman also jointly runs the Pharmacology and Analytical Core lab for the institution as well as co-directs the Pharmaceutical Development Center that has introduced over 6 compounds into the clinic over the past 7 years. He is the author of over 250 peer-reviewed publications and several books. His current research deals with the science of nutraceuticals and understanding how these can be specifically applied for prevention and treatment of inflammation and malignant disease.

Go back